Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677844 | 0.91 | FGFR1 (0.52) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4680717 | 0.89 | FGFR4 (0.48) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4678419 | 0.86 | FGFR1 (0.68) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4679796 | 0.86 | FGFR1 (0.46) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4678080 | 0.84 | CDK4 (0.53) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4677376 | 0.84 | FGFR1 (0.47) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4677272 | 0.83 | FGFR1 (0.74) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4682230 | 0.83 | FGFR4 (0.48) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4677312 | 0.81 | FGFR1 (0.56) | FGFR1FGFR4KDRFGFR2FGFR3 | |
| SCHEMBL4676145 | 0.78 | FGFR1 (0.42) | FGFR1FGFR2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1195378-B1 | Pyridotriazines and pyridopyridazines | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | EP | claimed |
| US-6683183-B2 | BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2004-01-27 | — | — | US | claimed |
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | KRAMER JAMES BERNARD (US) | 2002-05-23 | — | — | US | claimed |
| EP-1195378-A1 | Pyridotriazines and pyridopyridazines | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | claimed |
| EP-1195378-B1 | Pyridotriazines and pyridopyridazines | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6683183-B2 | BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | KRAMER JAMES BERNARD (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1195378-A1 | Pyridotriazines and pyridopyridazines | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | CDK1, CDK4, CDK2 | FGFR1 194/4885FGFR4 403/4885KDR 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.